RxDoctor Payments Data

Kelly O Driscoll, MD

Family Medicine · Telford, PANPI 1285831206

Payments from drug & device makers

$484in general payments, 2019–2025

Across 21 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$171
  • Vivus LLC$120
  • Amgen$72
  • GSK$47
  • Pfizer$23
  • Biohaven Pharmaceutical Holding Company Ltd.$21
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$484 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$124,558
Medicare patients
289
Services billed
2,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$34,896
OzempicSemaglutide29$27,390
JardianceEmpagliflozin22$26,307
MounjaroTirzepatide15$14,502
MyrbetriqMirabegron22$13,012
XareltoRivaroxaban14$8,121
Levothyroxine Sodium294$3,935
GemtesaVibegron11$3,642
SynthroidLevothyroxine Sodium42$3,535
Atorvastatin Calcium261$2,233
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,650
Escitalopram Oxalate75$1,412
Lisinopril178$1,200
Amlodipine Besylate167$1,184
Losartan Potassium109$1,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$34,89629 claims
Lilly USA, LLCMounjaro$19$14,50215 claims
Johnson & JohnsonXarelto$12$8,12114 claims
AbbVieSynthroid$171$3,53542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Telford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →